Reference
Chen H, et al. Cost-Effectiveness of Reimbursing Infliximab for Moderate to Severe Crohn's Disease in China. Advances in Therapy : 3 Dec 2019. Available from: URL: https://doi.org/10.1007/s12325-019-01150-x
Rights and permissions
About this article
Cite this article
Reimbursing infliximab for Crohn's disease cost effective in China. PharmacoEcon Outcomes News 843, 29 (2019). https://doi.org/10.1007/s40274-019-6456-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6456-7